|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 8,901,173
Summary
U.S. Patent 8,901,173, granted on November 25, 2014, to Regeneron Pharmaceuticals, Inc., broadly covers a class of monoclonal antibodies designed to treat inflammatory and autoimmune diseases through specific targeting mechanisms. This patent's scope involves unique antibody sequences, formulations, and methods of use for inhibiting cytokine activity, particularly interleukin-6 (IL-6). The claims extend protection over antibody structures, their therapeutic applications, and methods for production.
This report explores the patent's scope, the precise claims, their implications within the biologics patent landscape, and competitive overlaps. It further contextualizes the patent landscape with related patents, identifying key players, filings, and strategic significance within the therapeutics for autoimmune diseases.
1. Patent Abstract and Main Claims Overview
Abstract Summary
The patent primarily claims antibodies, specifically IL-6 receptor (IL-6R) antagonistic monoclonal antibodies, with unique amino acid sequences or binding characteristics. These agents are designed for pharmaceutical purposes, especially in inflammatory conditions such as rheumatoid arthritis, Castleman's disease, and other cytokine-mediated disorders.
Main Claims (Summary)
- Claim 1: Antibodies or antigen-binding portions thereof, with specific variable region sequences that bind IL-6R.
- Claim 2: Mutations or modifications of the antibody sequences that retain binding affinity.
- Claim 3: Pharmaceutical compositions comprising the claimed antibodies.
- Claims 4-10: Methods of inhibiting IL-6 or IL-6R activity, treating autoimmune or inflammatory diseases using the antibodies.
- Claims 11-15: Production methods, including hybridomas and recombinant techniques.
2. Scope of the Patent
a. Structural Coverage
The patent covers:
- Specific monoclonal antibodies with defined variable heavy (VH) and variable light (VL) chain amino acid sequences (Table 1).
- Variants, mutants, and humanized forms retaining IL-6R binding.
- Antibody fragments (Fab, scFv, etc.) with similar binding properties.
b. Functional Coverage
- Binding affinity to IL-6R.
- Therapeutic inhibition of IL-6 signaling pathways.
- Use in conditions involving cytokine storms, autoimmune diseases, and related indications.
c. Manufacturing and Formulation
- Recombinant expression systems.
- Compositions with carriers or excipients suitable for injection or infusion.
d. Methods of Treatment
- Administration protocols for autoimmune conditions.
- Dosing strategies.
3. Detailed Claims Analysis
| Claim Number |
Type |
Scope Details |
Implications |
| 1 |
Composition (Antibodies) |
Defines specific monoclonal antibody sequences with structural identifiers. |
Core claim establishing proprietary antibody candidates with defined sequences. |
| 2 |
Variants and Mutants |
Covers amino acid modifications that do not impair binding. |
Extends protection to engineered variants. |
| 3 |
Pharmaceutical compositions |
Including antibodies with carriers/excipients. |
Ensures claim scope over marketed formulations. |
| 4-10 |
Therapeutic methods |
Uses of the antibodies for treating specific autoimmune/inflammatory conditions. |
Broadens patent coverage across treatment modalities. |
| 11-15 |
Production methods |
Recombinant and hybridoma-based antibody production. |
Ensures control over manufacturing techniques. |
Sequences and Structural Claims
The patent discloses sequence IDs, primarily in Tables 2 and 3, listing heavy and light chain sequences, with modifications covered under dependent claims.
Example:
- Claim 1 antibody sequence: encompasses the VH and VL sequences identified as SEQ ID NOs (e.g., SEQ ID NO: 1 and 2).
- Variants include amino acid substitutions, deletions, or insertions within regions critical for binding, provided binding affinity exceeds a threshold (e.g., K_D < 10 nM).
4. Patent Landscape and Competitive Context
a. Key Patent Families
- Regeneron Patents: Focused on IL-6R antagonists, including REGN88 (sarilumab); their patent family includes US 8,629,153 and US 8,618,141.
- Eli Lilly and AbbVie: Hold patents on IL-6 inhibitors like tocilizumab, with notable claims relevant to the same therapeutic area.
- Other Notables: Several applications filed internationally, notably in WO 2013/172921, covering humanized anti-IL-6R antibodies and diagnostic methods.
b. Patent Filing Timeline
| Year |
Patent Family Area |
Assignee |
Notable Patents |
| 2002-2010 |
Anti-cytokine antibodies |
Multiple (Eli Lilly, Regeneron, others) |
Includes early IL-6 inhibitors |
| 2011-2015 |
IL-6R antibody development |
Regeneron, others |
US 8,901,173 issued in 2014 |
| Post 2015 |
Formulation and methods |
Multiple |
Ongoing litigations and filings |
c. Strategic Significance
The patent's broad claims over particular sequences and variants likely aims to prevent similar antibody therapies from entering the market, especially for indications like rheumatoid arthritis, where IL-6R antagonists are established.
5. Comparison with Similar Patents
| Patent |
Patent Holder |
Claim Focus |
Strengths |
Implications |
| US 8,629,153 |
Regeneron |
SARILUMAB (IL-6R antibody) sequences |
Similar target, overlapping sequences |
Potentially can challenge or be challenged by the '173 patent |
| US 8,618,141 |
Regeneron |
Related anti-IL-6R antibodies |
Broader antibody coverage |
Complements '173, provides strategic options |
| WO 2013/172921 |
Various |
Humanized IL-6R antibodies and diagnostic methods |
International coverage |
Expands patent landscape, possible licensing or challenge |
6. Implications for Patent Strategy and Industry
7. Key Regulatory and Policy Considerations
- Patent Term and Expiry:
- Expected patent expiration around 2032, considering 20-year term from filing (2010).
- Patent Term Extensions:
- Possible extensions for manufacturing delays or regulatory approval.
- Potential Compulsory Licenses:
- In case of public health emergencies or patent disputes.
8. Deep Dive: Therapeutic and Commercial Applications
Indications Covered
| Disease/Condition |
Relevance |
References |
| Rheumatoid arthritis |
Major application |
[1], [2] |
| Castleman's disease |
Specific indication |
[3] |
| Cytokine release syndrome |
Emerging use |
[4] |
| COVID-19 cytokine storm |
Investigational |
[5] |
Delivery Methods
- Intravenous infusion.
- Subcutaneous injection.
- Potential for sustained-release formulations.
9. Comparative Technologies and Future Trends
| Trend |
Impact on Patent Landscape |
Example Technologies |
| Biosimilars |
Increased patent litigations |
Corresponding to patent expiry |
| Bispecific antibodies |
New patent filings, possibly circumventing '173' |
e.g., BiTEs, dual-target antibodies |
| Personalized medicine |
Custom antibody sequences |
Genetic screening for optimal targeting |
10. Summary and Conclusions
- Scope: The patent provides robust protection over specific IL-6R antibody sequences, their variants, and methods of use in autoimmune diseases, particularly rheumatoid arthritis.
- Claims: Cover both composition and therapeutic application, including variants, manufacturing, and formulations.
- Landscape: Positioned within a competitive field featuring heavyweights like Regeneron, Eli Lilly, AbbVie, and others, with overlapping patent claims and filings.
- Strategic Considerations: Ongoing patent prosecution and potential challenges necessitate vigilant monitoring; licensing negotiations may be strategic for competitors.
- Competitive Edge: Proprietary antibody sequences with well-defined functional properties confer defensibility but require continual innovation to maintain market exclusivity.
Key Takeaways
- U.S. Patent 8,901,173 secures a significant position in the cytokine-targeted biologic space.
- The broad claims over specific sequences and methods offer strong barriers to entry but must be defended amidst overlapping claims.
- The patent landscape indicates a crowded field with escalating patent filings, necessitating strategic IP management.
- Continuous innovation, including the development of modified antibodies or bispecifics, will be essential to sustain competitive advantage.
- Ongoing monitoring of patent litigations, licensing opportunities, and emerging therapies remains critical.
FAQs
Q1: Does U.S. Patent 8,901,173 cover all anti-IL-6R monoclonal antibodies?
A: No. It specifically claims antibodies with designated variable region sequences and their variants. While it covers key molecules, other antibodies with different sequences not falling within the claimed scope are not protected.
Q2: Can companies develop biosimilar IL-6R monoclonal antibodies without infringing this patent?
A: Potentially, if the biosimilars differ significantly in sequence or are designed around the claims. However, detailed comparison of sequences and functional properties is necessary.
Q3: What is the expiration date of U.S. Patent 8,901,173?
A: Typically, utility patents filed around 2010 last 20 years from the priority date, suggesting expiration around 2030-2032, subject to patent term adjustments.
Q4: Are method claims in this patent enforceable?
A: Yes. Method claims related to treatment protocols and manufacturing are enforceable if infringing activity occurs.
Q5: How does this patent relate to existing IL-6 or IL-6R therapies like tocilizumab?
A: While tocilizumab's patent estate is extensive, this patent covers specific monoclonal antibody sequences and formulations, potentially providing alternative or complementary protection.
References
[1] KEGG DRUG database, "Tocilizumab," 2023.
[2] Lee, D., et al. "IL-6 inhibitors in rheumatoid arthritis: a review." Clin Ther, 2020.
[3] Arnold, J., et al. "Castleman’s Disease and IL-6 inhibitors." J Clin Immunol, 2017.
[4] Lee, C. and Walker, J. "Cytokine Storms and Therapeutic Interventions." Nat Med, 2021.
[5] Chen, X., et al. "Cytokine Modulation in COVID-19." J Exp Med, 2022.
More… ↓
⤷ Start Trial
|
